Professor and Chair
Division of Pulmonary Medicine
Section of Critical Care Medicine
https://orcid.org/0000-0002-3621-2422
Dr. Dhand is an internationally recognized researcher in the area of aerosolized medicine particularly with regard to the delivery of medications designed to treat chronic obstructive lung disease. Recent initiatives include (1) a critical analysis of the microbiome of nebulizers and related respiratory devices, which may lead to a change in the way in which we re-use tubing and aerosol chambers, and (2) the development of a tool that can be used to select the optimal inhaler device based on patient characteristics (i.e. a new approach to precision medicine applied to COPD treatment). Additionally, he is interested in muscle weakness and outcomes in patients admitted to the hospital.
Medical School
Postgraduate Institute, Chandigarh, India, 1978
National Board of Examinations (New Delhi, India)
Degree in Respiratory Medicine, 1979
Residency
Postgraduate Institute, Chandigarh, India
Postgraduate School
Research Associate, Virginia Mason Research Center
Research Associate, University of Washington-Seattle, WA
Fellowship
Pulmonary,
Postgraduate Institute, Chandigarh, India
Pulmonary & Critical Care Medicine, VA Medical Center, Boise, ID and University of Washington-Seattle, WA
Pulmonary & Critical Care Medicine, Loyola University Medical Center, IL
American Board of Internal Medicine
American Board of Internal Medicine, Pulmonary Disease
American Board of Internal Medicine, Critical Care Medicine
Fellow, American College of Chest Physicians
Fellow, American College of Physicians
Fellow, American Association of Respiratory Care
Elected to America's Top Physicians
Dhand R. Inhaled Anticancer Agents. In: Advances in Pulmonary Drug Delivery. Boca Raton: CRC Press. Chapter 5, p. 67-92.
Terry P, Heidel RE, Wilson AQ, Dhand R.
Risk of long COVID in patients with pre-existing chronic respiratory diseases: A systematic review and meta-analysis. BMJ Open Respir Res. 2025 Jan 30;12(1):e002528. doi: 10.1136/bmjresp-2024-002528.
Dhand R, Treat S, Ferris J, Terry PD, Walker T, Elder S, Church D, Dennis D, Faircloth B, Onar G, Heidel R.E, Biney I, Valdes M, Bhagat M, Fuerst N, Cusick S.
Safety, efficacy, and feasibility of nebulized long-acting bronchodilators vs short-acting bronchodilators in hospitalized patients with acute exacerbations of COPD: A phase IV, randomized, parallel-group clinical trial. Chest Pulm.. 2024,Volume 2, Issue 4,100105,ISSN 2949-7892,https://doi.org/10.1016/j.chpulm.2024.100105
Dhand R, Ferris J, Onar G, Terry P, Heidel ER, Nemykina Y.
Serum alpha-1 antitrypsin levels and phenotypes among patients with COPD and asthma seen at an academic tertiary pulmonary clinic in East Tennessee. CHEST. 2024,Volume 166, Issue 4, Supplement,Pages A4842-A4843,ISSN 0012-3692,https://doi.org/10.1016/j.chest.2024.06.2873
Dhand R, Hess MW, Yohannes AM.
Recalibrating perceptions and attitudes toward nebulizers versus inhalers for maintenance therapy in COPD: Past as prologue. Int J Chron Obstruct Pulmon Dis. 2024 Nov 28;19:2571-2586. doi: 10.2147/COPD.S491275. eCollection 2024.
Biney I, Ari A, Barjaktarevic IZ, Carlin B, Christiani DC, Cochran L, Drummond MB, Johnson K, Kealing D, Kuehl PJ, Li J, Mahler DA, Martinez S, Ohar J, Radonovich L, Sood A, Suggett J, Tal-Singer R, Tashkin D, Yates J, Cambridge L, Dailey PA, Mannino DM, Dhand R..
Guidance on mitigating the risk of transmitting respiratory infections during nebulization by the COPD foundation nebulizer consortium. Chest. 2024 Mar;165(3):653-668. doi: 10.1016/j.chest.2023.11.013. Epub 2023 Nov 15.
Terry PD, Dhand R..
The 2023 gold report: Updated guidelines for inhaled pharmacological therapy in patients with stable COPD. Pulm Ther. 2023 Jul 20. doi: 10.1007/s41030-023-00233-z. Online ahead of print.
Li J, Liu K, Lyu S, Jing G, Dai B, Dhand R, Lin HL, Pelosi P, Berlinski A, Rello J, Torres A, Luyt CE, Michotte JB, Lu Q, Reychler G, Vecellio L, de Andrade AD, Rouby JJ, Fink JB, Ehrmann S..
Aerosol therapy in adult critically ill patients: A consensus statement regarding aerosol administration strategies during various modes of respiratory support. Ann Intensive Care. 2023 Jul 12;13(1):63. doi: 10.1186/s13613-023-01147-4.
Terry PD, Heidel RE, Dhand R.
The association of preexisting severe asthma with COVID-19 outcomes. Curr Opin Pulm Med. 2023 May 1;29(3):215-222. doi: 10.1097/MCP.0000000000000954. Epub 2023 Mar 17.
Swanson CS, Dhand R, Cao L, Ferris J, Elder CS, He Q.
Microbiome-scale analysis of aerosol facemask contamination during nebulization therapy in hospital. J Hosp Infect. 2023 Apr;134:80-88. doi: 10.1016/j.jhin.2023.01.008. Epub 2023 Jan 20.
Hamilton M, Anderson M, Dhand R, Patmore O, Prime D, Taylor E..
In vitro drug delivery of a fixed-dose combination of fluticasone furoate/umeclidinium/vilanterol from a dry powder inhaler. J Aerosol Med Pulm Drug Deliv.
Swanson CS, Dhand R, Cao L, Ferris J, Elder CS, He Q.
Microbiome-scale analysis of aerosol facemask contamination during nebulization therapy in the hospital. J Hosp Infect. 2023 Jan 20:S0195-6701(23)00019-1. doi: 10.1016/j.jhin.2023.01.008. Online ahead of print.
Pleasants RA, Chan AH, Mosnaim G, Costello RW, Dhand R, Schworer SA, Merchant R, Tilley SL..
Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease. Respir Med. 2022 Dec;205:107038. doi: 10.1016/j.rmed.2022.107038. Epub 2022 Nov 7.
Swanson CS, Dhand R, Cao L, Ferris J, Elder CS, He Q.
Microbiome profiles of nebulizers in hospital use. J Aerosol Med Pulm Drug Deliv. 2022 Aug;35(4):212-222. doi: 10.1089/jamp.2021.0032. Epub 2022 Feb 25.
Li J, Alolaiwat A, Fink JB, Dhand R.
Aerosol-generating procedures and virus transmission. Respir Care. 2022 Aug;67(8):1022-1042. doi: 10.4187/respcare.10160. Epub 2022 Apr 6.
Li J, A Alolaiwat A, J Harnois L, Fink JB, Dhand R.
Mitigating fugitive aerosols during aerosol delivery via high-flow nasal cannula devices. Respir Care. 2022 Apr;67(4):404-414. doi: 10.4187/respcare.09589. Epub 2021 Nov 17.
Swanson CS, Dhand R, Cao L, Ferris J, Elder CS, He Q.
Microbiome-based source identification of microbial contamination in nebulizers used by inpatients. J Hosp Infect. 2022 Apr;122:157-161. doi: 10.1016/j.jhin.2022.01.008. Epub 2022 Jan 23.
Dhand R.
Inhaled tobramycin for treatment of ventilator-associated pneumonia: The interplay of patient, drug, and device. Respiratory Care. Respiratory Care January 2022, 67 (1) 151-153; DOI: https://doi.org/10.4187/respcare.09852
Ohar JA, Ferguson GT, Mahler DA, Drummond MB, Dhand R, Pleasants RA, Anzueto A, Halpin DMG, Price DB, Drescher GS, Hoy HM, Haughney J, Hess MW, Usmani OS..
Measuring peak inspiratory flow in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2022 Jan 6;17:79-92. doi: 10.2147/COPD.S319511. eCollection 2022.
Valdes M, Faradji D, Ferris J, Dhand R. Correlation of subjective perceived activity and weakness score (PAWS) with maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP) and peak inspiratory flow rate (PIFR Presented at American Thoracic Society; 2023 May 19; Washington DC.
Treat S, Forsyth C, Kumar G, Biney I, Ferris J, Heidel E, Terry P, Dhand R. Antibiotic usage in patients experiencing readmissions for acute exacerbations of chronic obstructive pulmonary disease Presented at American Thoracic Society 2022 ; 2022 May-13; San Francisco, CA .
Bhagat M, Sharma N, Dudney TM, Dhand R, Gardner K. An unexpected encounter: primary ewing sarcoma of the lung Presented at American Thoracic Society 2022 ; 2022 May-13; San Francisco, CA .
Bhagat M, Sharma N, Dudney TM, Dhand R, Bevill B, Branca P, McCormack M, Heidel R, Green J, Soto F. Use of inhaled epoprostenol delivered by high flow nasal cannula in patients with severe hypoxemic respiratory failure secondary to covid-19 Presented at American Thoracic Society 2022 ; 2022 May-13; San Francisco, CA .
Sharma N, Bhagat M, Dudney T, Dhand R, Bevill B, Branca P, McCormack M, Heidel R, Green J, Soto F. Use of Inhaled Epoprostenol Delivered by High-Flow Nasal Cannula in Patients with Severe Acute Hypoxemic Respiratory Failure Secondary to COVID-19. Presented at American Thoracic Society 2022 Conference; 2022 May-13; San Francisco, California.
Shali L, Terry P, Kumar G, Worth H, Ferris J, Norwood D, Heidel E, Dhand R. Associations Among Social Determinants of Health and Quality of Life in Rural Appalachia. Presented at American Thoracic society ; 2022 May-15; San Fransisco, California.
TopThe University of Tennessee Graduate School of Medicine
1924 Alcoa Highway
Knoxville, Tennessee 37920 | 865-305-9290
Copyright © 2024